Grants for Alzheimers Disease Drug Discovery (R21)
The summary for the Grants for Alzheimers Disease Drug Discovery (R21) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Grants for Alzheimers Disease Drug Discovery (R21): Purpose. The goal of this FOA is to advance the discovery of new, efficacious therapies for the treatment, delay of progression, or prevention of Alzheimers disease (AD), mild cognitive impairment (MCI) and age-related cognitive decline. This FOA encourages the early stages of drug discovery necessary to identify promising disease-modifying therapies as well as treatments aimed at ameliorating the cognitive and neuropsychiatric/behavioral symptoms characteristic of Alzheimers disease. Studies aimed at the discovery and testing of therapies directed at a variety of established as well as novel therapeutic targets are encouraged. The goal is not to duplicate or compete with pharmaceutical companies but to encourage the process of discovering new, innovative, and effective therapeutics for the prevention and treatment of the cognitive impairment and behavioral symptoms associated with Alzheimer's disease Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
Federal Grant Title: | Grants for Alzheimers Disease Drug Discovery (R21) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAS-10-151 |
Type of Funding: | Grant |
CFDA Numbers: | 93.866 |
CFDA Descriptions: | Aging Research |
Current Application Deadline: | May 07, 2013 |
Original Application Deadline: | May 07, 2013 |
Posted Date: | Mar 22, 2010 |
Creation Date: | Mar 22, 2010 |
Archive Date: | Jun 07, 2013 |
Total Program Funding: | |
Maximum Federal Grant Award: | $200,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Nathan Shock Centers Coordinating Center (U24 Clinical Trial Not Allowed)
- • Nathan Shock Centers of Excellence in Basic Biology of Aging (P30 Clinical Trial Not Allow...
- • Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (...
- • Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumul...
- • Research Training in Aging for Medical Students (T35)
- • Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...
- • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...
- • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
- More Grants from the National Institutes of Health
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
- • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...